Recent developments surrounding Moderna Inc. $MRNA have captured the attention of investors and analysts in the healthcare sector. The company’s shares have significantly declined following a disappointing report on vaccine sales in the first quarter and delays in regulatory approval for its combination flu and Covid vaccines.